Testing nivolumab for melanoma spread to the limb skin
Treatments studied
Part of Cancer, Skin clinical trials.
This trial studies nivolumab, an immune medicine, for melanoma that has spread to the skin along a limb (called in-transit metastases). It’s given after a procedure that delivers higher treatment levels to the affected limb, with the goal of shrinking the melanoma and improving outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older and can sign consent before any study steps begin
- Your melanoma has spread to the limb skin (in-transit metastases) confirmed by a lab test, with possible nearby lymph node spread
- You have measurable melanoma that is at least 5 mm in size
- Your general health is good enough for study treatment (ECOG 0 to 2)
- Your expected survival is at least 6 months
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if injecting two immunotherapy drugs (ipilimumab and nivolumab) just under the skin can help prevent high-risk stage II melanoma from spreading. It is for people who have recently had a thick melanoma removed and have not yet had a sentinel node biopsy.
This study tests a combination of three drugs (relatlimab, ipilimumab, and nivolumab) as a first treatment for advanced melanoma that cannot be removed by surgery. All participants will receive the drug combination, and the study will look at safety and how well it works.
This trial is testing a combination of two immunotherapy drugs (anti-LAG-3 and anti-PD-1 antibodies) to see if they work better than standard treatment for people with advanced melanoma that hasn't been treated before. It may be an option if you have not yet received any systemic therapy for your melanoma.
This trial tests whether giving immunotherapy (anti-PD1) before and after surgery can help treat melanoma that has spread to nearby lymph nodes or skin. It is for people whose melanoma can be removed surgically, and who either haven't had systemic treatment before or whose melanoma has returned after prior immunotherapy or targeted therapy.
This trial tests a combination of three immunotherapy drugs (relatlimab, nivolumab, and ipilimumab) for people with melanoma that has spread to the brain. It aims to see if this treatment can shrink brain tumors and improve outcomes.
This trial studies how the immune system and body metabolism change in people with in-transit melanoma (melanoma spread to nearby skin). It aims to understand what’s happening in these lesions and how that information could guide better treatment.
Hear when a new Melanoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.